Purpose A phase III study adding aprepitant to a 5HT3 receptor antagonist (5HT3-RA) plus dexamethasone in germ cell tumor (GCT) patients treated with 5-day cisplatin combination chemotherapy demonstrated a significant improvement in complete response (CR) (J Clin Onc 30:3998-4003, 2012). Fosaprepitant has demonstrated non-inferiority compared to aprepitant in single-day cisplatin chemotherapy and is approved as a single-dose alternative. This single-arm phase II study is the first clinical trial evaluating fosaprepitant in patients receiving multi-day cisplatin regimen. Methods GCT patients receiving a 5-day cisplatin combination chemotherapy were enrolled. Fosaprepitant 150 mg was given IV on days 3 and 5. A 5HT3-RA days 1-5 (days 1, 3, and 5, if palonosetron) plus dexamethasone 20 mg days 1 and 2 and 4 mg po bid days 6, 7, and 8 was administered. Rescue antiemetics were allowed. The primary objective was to determine the CR rate-no emetic episodes or use of rescue medications. Accrual of 64 patients was planned with expected CR > 27 %. Results Sixty-five patients were enrolled of whom 54 were eligible for analysis. Median age was 33. Fifty-one patients received bleomycin, etoposide, and cisplatin (BEP) chemotherapy. CR was observed in 13 (24.1 %) patients (95 % Agresti-Coull binomial C.I. 14.5 %, 37.1 %).
Introduction
Germ cell tumors (GCTs) represent the most common carcinoma in men ages 15 to 35 years. There is an estimated 8430 new cases to be diagnosed in the USA in 2015 [1] . Testicular cancer has become the model for curable malignancy after the introduction of cisplatin-based combination chemotherapy [2] . Acute and delayed nausea and vomiting is a universal adverse effect of cisplatin chemotherapy. Significant progress has been achieved in the prevention of chemotherapy-induced nausea and vomiting (CINV). Despite these advances, quality of life in patients receiving combination chemotherapy continues to be impaired due to CINV [3] . The addition of the oral brain-penetrant neurokinin-1 receptor antagonist (NK1-RA) aprepitant, to a 5-hydroxytryptamine-3 receptor antagonist (5HT3-RA) and dexamethasone improved the prevention of CINV in patients receiving highly emetogenic single-day cisplatin chemotherapy [4] [5] [6] . In the Hoosier Cancer Research Network (HCRN), a randomized double-blind placebo controlled study was conducted with patients receiving 5-day cisplatin-based combination chemotherapy. In this phase III study, patients received a 5HT3-RA plus dexamethasone plus either aprepitant or placebo. This study demonstrated a significant improvement in complete response (CR) rate of 42 versus 13 % (P < 0.001) favoring aprepitant [7] .
The availability of an intravenous (IV) formulation of NK1-RA would provide further accessibility to this antiemetic class. Fosaprepitant, a water-soluble prodrug of aprepitant, is available in IV formulation. It is rapidly converted to the active form (aprepitant) by phosphatase activities delivering the same aprepitant exposure with comparable antiemetic effect [8] .
A randomized double-blind phase III study was conducted to assess the efficacy and safety of fosaprepitant in the prevention of CINV in cisplatin-naive patients who were treated with chemotherapy regimens that included single-day cisplatin ≥ 70 mg/m 2 [9] enrolled over 2200 patients and demonstrated that a single dose of intravenous fosaprepitant was non-inferior to standard 3-day oral aprepitant. Here, we report the results of the first clinical trial evaluating fosaprepitant in patients receiving multiday cisplatin combination chemotherapy.
Methods

Patient selection
Eligible patients were ≥ 15 years of age with histologically or cytologically confirmed diagnosis of GCT who were scheduled to receive a standard 5-day cisplatin-based chemotherapy regimen. Patients who received prior chemotherapy cycles were eligible for this study. Patients had to be without nausea or vomiting for 24 h before study entry and no antiemetic use for 72 h prior to starting protocol therapy. Absolute neutrophil count ≥1500 cells/μL, WBC count ≥3000 cells/μL, platelet count ≥100,000 cells/μL, AST and ALT ≤3 × upper limit of normal, bilirubin ≤1.5 × upper limit of normal, and creatinine less than 2 mg/dL were among inclusion criteria. Patients should have had an ECOG performance status of 0-2 and no active central nervous system (CNS) metastasis.
This single-arm HCRN phase II study was conducted from 2013 to 2015 after approval by each site's institutional review board. Informed consent was obtained from all individual participants included in the study.
Study design and treatment regimen
All participating patients received combination chemotherapy utilizing cisplatin 20 mg/m 2 × 5 days. All patients received an antiemetic regimen consisting of dexamethasone 20 mg orally daily on days 1 and 2 then 4 mg orally BID (twice daily) on days 6, 7, and 8. A 5HT3-RA was administered to all patients 30 min before starting chemotherapy: ondansetron 8 mg orally BID on days 1 to 5 or palonosetron 0.25 mg IV on days 1, 3, and 5. Fosaprepitant 150 mg was administered IV on days 3 and 5 over 20-30 min (Table 1) . Patients were permitted to take rescue therapy of the treating investigator's choice for nausea and/or emesis/retching based on clinical circumstances. No additional doses of 5HT3-RA, dexamethasone, or fosaprepitant were given during the acute or delayed treatment periods. Patients who required rescue therapy were permitted to continue the study at the discretion of the treating investigator and in consultation with the patient.
The primary endpoint was complete response (CR) of both acute (days 1 through 5) and delayed (days 6 through 8) CINV, defined by no emetic episodes or use of rescue medications. Secondary endpoints included incidence of emetic episodes via patients logs (days 1 through 8), use of rescue medications (days 1 through 8), patient's self-reported assessment of nausea (days 1 through 8) using a 0-100-mm visual analog scale (VAS), safety, and toxicity.
Study visits and assessment procedures
In the pre-study period, all pertinent demographics (age, gender, height, and weight) and medical data (site and A diary of days 1 through 8 of the chemotherapy cycle was provided to all patients enrolled in the study. Patients were asked to complete a daily log of any episodes of vomiting or retching and the day and time of these episodes. The use of rescue therapy, defined as any medication taken to treat established nausea or emesis, was also recorded. A 100-mm horizontal VAS was utilized for patients to rate nausea in the past 24 h on days 1 through 8 from no nausea to the worst nausea. A VAS score of 0 to 5 mm was considered as no nausea.
Statistical methods
The CR rate of aprepitant in GCT patients receiving 5-day cisplatin-based combination chemotherapy was 42 % [7] . We expected fosaprepitant to have similar CR rate. A onesided score test was used to compare the CR rate of fosaprepitant with the historical data of aprepitant. Denoting the CR rate of fosaprepitant as p, the hypotheses are H 0 : p ≤ 27 % versus H A : p ≥ 27 %. A CR rate of fosaprepitant that is no worse than 15 % lower than aprepitant was considered worth for further investigation. Enrollment of 64 patients was required to attain a power of 0.80 with type I error level as 0.05.
Continuous variables were summarized by mean, median, and range. Categorical variables were summarized by frequencies and percentages. Overall CR was tested according to the aforementioned hypotheses. In addition, 95 % confidence interval of Agresti-Coull type was constructed for the overall CR. Adverse events were summarized by their grades and types.
Results
Patient characteristics
From January 2013 till May 2015, patients with GCT who were scheduled to receive 5-day cisplatin chemotherapy were enrolled. A total of 65 patients were enrolled in the study. One patient had a reaction to the infusion and was taken off the study. Ten patients were not evaluable because they did not complete the VAS on all 8 days. Hence, 54 patients were evaluable and eligible for analysis. Demographic and treatment data are listed in Table 1 . Median age was 33 (range 15-66). All patients were Caucasian and male. Eastern Cooperative Oncology Group (ECCOG) Performance Status was 0 in 59 (92.2 %) patients, 1 in 4 (6.2 %) patients, and 2 in 1 (1.6 %) patient. Chemotherapy regimen consisted of bleomycin, etoposide, and cisplatin (BEP) in 51 (79.7 %) patients; etoposide, and cisplatin (EP) in 10 (15.6 %) patients; vinblastine, ifosfamide, and cisplatin (VeIP) in 2 (3.1 %) patients; and cisplatin/epirubicin in 1 (1.6 %) patient. All evaluable patients received fosaprepitant 150 mg IV on days 3 and 5. Among evaluable patients, 4 received ondansetron and and 50 received palonosetron. All evaluable patients received 5 days of dexamethasone. Among the evaluable patients, 50 (92.6 %) were chemotherapy-naïve. Table 2 depicts patient and treatment characteristics.
Efficacy endpoints
Primary and secondary endpoints were analyzed in the 54 evaluable patients. Complete response (CR), defined by no emetic episodes and no use of rescue medications, was observed in 13 (24.1 %) patients in the overall treatment BEP bleomycin, etoposide, cisplatin; EP etoposide, cisplatin; VeIP vinblastine, ifosfamide, cisplatin period day 1-8 (95 % Agresti-Coull binomial C.I. 14.5 %, 37.1 %). This was insufficient to reject the null hypothesis H 0 : p ≤ 27 % (p = 0.68). CR was observed in 16 (29.6 %) patients during the acute phase (days 1 through 5) and 25 (46.3 %) patients in the delayed phase (days 6 through 8). Figure 1 depicts the percentage of CR in the acute, delayed, and overall phases. Sixteen (29.6 %) patients had at least 1 emetic episode. Total number of emetic episodes was 29. Nine patients had 1 emetic episode, 2 patients had 2 episodes, 4 patients had 3 episodes, and 1 patient had 4 emetic episodes. The largest number of emetic episodes occurred on days 3, 5, and 7 with 5 patients having an emetic episode on each of these days. The fewest number of emetic episodes occurred on days 1 and 6 with 2 patients having an emetic episode on these days. 
Safety
Sixty-four patients were evaluable for toxicity. Administration of fosaprepitant was well tolerated. There was a total of seven grade III or IV toxicity events in this study that were possibly, probably, or definitely related to the study drug. Two patients had grade III toxicity consisting of leukopenia and thrombocytopenia. Four patients had grade IV toxicity consisting of leukopenia and neutropenia. One patient had grade IV toxicity consisting of febrile neutropenia. There were no cases of reaction at the infusion site attributable to fosaprepitant infusion in this study.
Discussion
Severe CINV were common adverse events associated with certain chemotherapeutic regimens and forced a substantial number of patients to delay or even refuse potentially curative therapy [10] . Compelling advances have been achieved in recent years in the treatment of CINV. However, emesis continues to be among the most distressing and feared adverse effects of chemotherapy [11] . Prior to the introduction of ondansetron, the first 5HT3-RA, a typical patient with testicular cancer would experience a significant number of emetic episodes during the acute and delayed phases of a cisplatinbased combination chemotherapy cycle [12] . The introduction of ondansetron was fundamental in preventing acute nausea and vomiting associated with cisplatin-based chemotherapy [13, 14] . More recently, patients receiving multi-day cisplatin experience more severe symptoms of CINV on later days of the chemotherapy cycle (days 3-5) as well as delayed CINV on days 6-8 [15] . The addition of dexamethasone in phase III studies resulted in further improvement in the prevention of acute CINV [16] . Delayed CINV was not adequately controlled by 5HT3-RA and dexamethasone [17] .
Aprepitant, a NK1-RA, demonstrated efficacy in controlling both acute and delayed CINV, and hence it was combined with previous antiemetic regimens. Aprepitant was initially given for 5 days [18] , but eventually a 3-day course was deemed sufficient [6] . Aprepitant proved to be efficacious in preventing CINV in a randomized double-blind placebo-controlled trial which enrolled cisplatin-naïve patients who were treated with chemotherapy regimens including cisplatin ≥70 mg/m 2 administered on a single day [6] . In the HCRN, a phase III study was conducted to test the efficacy of aprepitant in patients undergoing a 5-day cisplatin-based combination chemotherapy regimen [7] . In this randomized double-blind placebo-controlled crossover study, 42 % of patients achieved a CR, defined as no emetic episodes and no use of rescue medications, with aprepitant compared to 13 % with placebo (p < 0.001).
An intravenous formulation of a NK1-RA was developed. Fosaprepitant is an IV water-soluble prodrug which rapidly converts to aprepitant within 30 min of administration [19] . A phase III trial evaluated single-dose fosaprepitant 150 mg IV in combination with granisetron and dexamethasone compared to a regimen of placebo, granisetron, and dexamethasone [20] . The arm containing fosaprepitant achieved a higher complete response than the control arm; 64 vs. 47 % (p = 0.0015), and fosaprepitant was more effective in both acute and delayed phases. A phase III randomized, doubleblind, non-inferiority study was conducted comparing fosaprepitant to aprepitant in chemotherapy-naïve patients receiving cisplatin ≥70 mg/m 2 [9] . A single dose of IV fosaprepitant was shown to be non-inferior to standard 3-day oral aprepitant at preventing CINV in patients receiving single-day cisplatin. Limited data is available with fosaprepitant in patients receiving a 5-day cisplatin combination chemotherapy regimen.
The HCRN conducted this single-arm phase II study as a first evaluation of fosaprepitant in patients receiving 5-day cisplatin-based combination chemotherapy for GCT. The use of dexamethasone was restricted to days 1 and 2 of the acute phase in the chemotherapy cycle in an attempt to decrease the long-term adverse effects of corticosteroids including hyperglycemia, avascular necrosis of the hip, cataracts, anxiety, and obesity [21] [22] [23] .
In the phase II study reported here, fosaprepitant combined with dexamethasone and 5HT3-RA was very well tolerated with minimal grade III or IV toxicities. However, the CR rate observed in this study appears to be significantly lower than our previous study with aprepitant. Fosaprepitant had a CR rate of 24.1 % in this study compared to a CR rate of 42 % with aprepitant [7] . While there may be several factors that contributed to the low CR rate, a notable one is that 15 % of the patients were not evaluable for the primary endpoint due to incomplete patient logs.
To the best of our knowledge, this is the first clinical trial evaluating fosaprepitant in patients receiving 5-day cisplatinbased chemotherapy regimens for GCT. The data in this small phase II study, in contrast to our prior phase III study, appears to indicate a significantly lower CR rate with the substitution of fosaprepitant for aprepitant.
